Insulet’s second quarter was marked by strong revenue expansion but a sharp negative market reaction, as investors focused on emerging challenges in the company’s type 2 diabetes segment. While broad-based demand for Omnipod drove growth across both U.S. and international markets, CEO Ashley McEvoy acknowledged that lower-than-expected retention rates among new type 2 users weighed on results. McEvoy stated, “We should have identified the issue sooner,” signaling a more cautious approach to comm

Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]

Type 2 retention challenges force management to trim full-year outlook despite revenue beat.

Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.

Insulet stock has fallen sharply over the past year, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading below what the underlying business may be worth. Over the past 12 months, Insulet has declined 54.1%, which means the market has already priced in a lot of pessimism. The recent cut to full year revenue growth expectations after an earnings beat can weigh on sentiment, while any renewed confidence in Insulet's long...

Insulet's (PODD) execution challenges in serving Type 2 diabetes patients, upcoming competition in p

Zillow downgraded, Global Payments upgraded: Wall Street's top analyst calls

Investing.com -- JPMorgan downgraded insulin pump maker Insulet to Neutral from Overweight, citing slowing U.S. sales growth, rising attrition among Type 2 diabetes patients and a weaker-than-expected outlook for 2027, while slashing its price target to $152 from $275.

Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.

In early August 2026, Insulet Corporation reported Q2 results showing US$801.7 million in sales and US$95.0 million in net income, then issued new guidance calling for total GAAP revenue growth of 17%–19% for Q3 2026 and 21%–23% for full-year 2026. At the same time, management cut full-year revenue expectations due to weaker-than-hoped retention and utilization among Type 2 diabetes users, despite strong overall Omnipod growth and higher international guidance. We’ll now examine how the...

Moby summary of Insulet Corporation's Q2 2026 earnings call

A modest forecast reduction raised larger questions about Omnipod's competitive position and future U.S. growth.

Insulet stock crashed Wednesday after lowering sales guidance for its body-worn insulin pump, Omnipod, in the back half of the year.

Insulet Corp (PODD) raises full-year international outlook but lowers U.S. growth guidance amid Type 2 onboarding execution issues.

Insulet lowers its full-year revenue growth outlook, even after earnings and revenue handily beat expectations.

Insulet (NASDAQ:PODD) reported second-quarter revenue growth of 23% on a constant-currency basis, supported by demand for its Omnipod insulin-delivery system in the U.S. and international markets, while raising its international outlook and reducing its U.S. and total-company revenue-growth expectat

The diabetes device maker exceeded second-quarter revenue guidance but reduced its full-year U. S.

The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Insulet (PODD) delivered earnings and revenue surprises of +15.28% and +1.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

GE HealthCare (GEHC) delivered earnings and revenue surprises of +8.65% and +0.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Insulet will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Last week’s chip-led selloff showcased just how quickly sentiment on AI can shift and drive a rotation out of tech stocks. Goldman Sachs outlined three investment themes to play for investors worried about AI overexposure in their portfolio.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 13.3% over the past six months, topping the S&P 500 by 2.5 percentage points.

Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that generate even more profits, creating a virtuous cycle of returns.

ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.